NCT01527916

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 438 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Detailed description

This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 410 adults with mild to moderate Alzheimer's disease. Subjects will be randomized to one of 5 treatment groups (ABT-126, donepezil or placebo) for a 24-week treatment period.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	placebo	Placebo Comparator
DRUG	donepezil	Active Comparator
DRUG	ABT-126	low dose, middle dose, high dose

Timeline

• Start date: 2012-02-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2012-02-07
• Last updated: 2014-11-19

Locations

33 sites across 6 countries: United States, Poland, Russia, South Africa, Ukraine, United Kingdom